Impact of the Recipient’s Pre-Treatment Blood Lymphocyte Count on Intended and Unintended Effects of Anti-T-Lymphocyte Globulin in Allogeneic Hematopoietic Stem Cell TransplantationAlexander Nikoloudis, Johannes Clausen, Veronika Buxhofer‐Ausch et al.|Cells|2023Cited by 5
Adverse impact of a high<scp>CD4</scp>/<scp>CD8</scp>ratio in the allograft may be overcome by methotrexate‐ but not mycophenolate‐ or post‐transplant cyclophosphamide‐based graft versus host disease prophylaxisAlexander Nikoloudis, Johannes Clausen, Petra Hasengruber et al.|European Journal Of Haematology|2023Cited by 5
Comparison of Benefits and Risks Associated with Anti-T-Lymphocyte Globulin (ATLG) Serotherapy in Methotrexate (MTX)- versus Mycophenolate Mofetil (MMF)-Based Hematopoietic Stem Cell TransplantationAlexander Nikoloudis, Johannes Clausen, Irene Straßl et al.|Transplantology|2023Cited by 3
Allogeneic Stem Cell Transplantation in Multiple Myeloma: Risk Factors and Outcomes in the Era of New Therapeutic Options—A Single-Center ExperienceIrene Straßl, Johannes Clausen, Alexander Nikoloudis et al.|Cancers|2023Cited by 3
The impact of tacrolimus levels on acute GVHD and transplant outcomes in haploidentical hematopoietic stem cell transplantation: A retrospective analysisAlexander Nikoloudis, Johannes Clausen, Veronika Buxhofer‐Ausch et al.|Cell Transplantation|2025Cited by 2